Return to homepagePandemic Pact

Broad-based spike protein stalk-based vaccine platform for SARS-CoV-2 and other coronaviruses

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R21AI166840-01

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2023

  • Known Financial Commitments (USD)

    $196,250

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    Gary R Whittaker

  • Research Location

    United States of America

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project Summary/Abstract We propose to develop a subunit vaccine for SARS-CoV-2, using a structure-based approach targeting conserved and functionally essential domains in the stalk region of the viral spike protein. We expect our vaccine platform to be applicable and effective across a wide range of existing and emerging coronaviruses. As our system is based on expression in E. coli is it expected to be cost-effective, and our stalk-based approach is specifically designed to cover a range of distinct coronaviruses. However, it is important to note that our vaccine platform is highly flexible, with the antigen able to be re-engineered rapidly in the face of a novel coronavirus that may emerge, and for which the vaccine developed in this application is not effective.